Laura W. Lang
Laura W. Lang's purchase track record
Laura W. Lang has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/2/2022 | VRM | $20K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
VFC Upgraded by Piper Sandler and Truist Amid Vans Turnaround. V.F. Corporation received upgrades from Piper Sandler and Truist Securities, with analysts citing positive signs in the Vans turnaround. These moves follow a period of strong price action, as the stock is currently trading near its 52-week high. The upgrades suggest growing confidence in the company's ability to sustain its recent momentum.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Vroom (VRM) noted as e‑commerce sector sees growth. Yahoo reports that ExtraMile and Loop are expanding their e‑commerce programs. Vroom runs an online platform for buying and selling vehicles, so broader growth in e‑commerce services may influence its market environment. The stock is currently near the bottom of its 52‑week range.
Transaction History
| OSCR | ▲ Buy | Grant | 8,475 | $0 | 6/4/2026 | View on chart |
| VFC | ▲ Buy | Grant | 11,977 | $200K | 5/22/2026 | View on chart |
| VFC | ▲ Buy | Grant | 13,285 | $167K | 6/4/2025 | View on chart |
| OSCR | ▲ Buy | Grant | 14,134 | $0 | 6/4/2025 | View on chart |
| VRM | ▲ Buy | Grant | 3,820 | $0 | 3/12/2025 | View on chart |
| OSCR | ▲ Buy | Grant | 8,974 | $0 | 6/6/2024 | View on chart |
| VFC | ▲ Buy | Grant | 7,288 | $0 | 5/28/2024 | View on chart |
| VRM | ▲ Buy | Grant | 97,656 | $0 | 6/15/2023 | View on chart |
| OSCR | ▲ Buy | Grant | 19,751 | $0 | 6/8/2023 | View on chart |
| VFC | ▲ Buy | Grant | 5,014 | $0 | 5/26/2023 | View on chart |
| OSCR | ▲ Buy | Grant | 31,506 | $0 | 12/7/2022 | View on chart |
| VRM | ▼ Sell | Open Market | 7,204 | $7K | 12/7/2022 | View on chart |
| VRM | ▲ Buy | Grant | 81,967 | $0 | 6/16/2022 | View on chart |
| VRM | ▲ Buy | Open Market | 15,000 | $20K | 6/2/2022 | View on chart |
| VFC | ▲ Buy | Grant | 1,986 | $0 | 5/24/2022 | View on chart |
| VFC | ▲ Buy | Option Exercise | 7,429 | $251K | 12/9/2021 | View on chart |
| VFC | ▼ Sell | Open Market | 7,429 | $568K | 12/9/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Oscar Health Analyst Target Rises to $34.19
Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.
Oscar Health Analyst Target Rises to $34.19. Analysts raised the consensus price target for Oscar Health by 12.09% to $34.19. This adjustment follows recent updates to the company's earnings roadmap and new product initiatives. The stock is currently trading near the upper end of its 52-week range, reflecting renewed interest in its growth prospects.